Copyright Reports & Markets. All rights reserved.

Global Peptides Biosimilars Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Peptides Biosimilars Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Glucagon
    • 1.2.3 Calcitonin
  • 1.3 Market by Application
    • 1.3.1 Global Peptides Biosimilars Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Oncology
    • 1.3.3 Chronic Diseases
    • 1.3.4 Autoimmune Diseases
    • 1.3.5 Blood Disorders
    • 1.3.6 Growth Hormone Deficiency
    • 1.3.7 Infectious Diseases
    • 1.3.8 Other Diseases
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Peptides Biosimilars Market Perspective (2016-2027)
  • 2.2 Peptides Biosimilars Growth Trends by Regions
    • 2.2.1 Peptides Biosimilars Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Peptides Biosimilars Historic Market Share by Regions (2016-2021)
    • 2.2.3 Peptides Biosimilars Forecasted Market Size by Regions (2022-2027)
  • 2.3 Peptides Biosimilars Industry Dynamic
    • 2.3.1 Peptides Biosimilars Market Trends
    • 2.3.2 Peptides Biosimilars Market Drivers
    • 2.3.3 Peptides Biosimilars Market Challenges
    • 2.3.4 Peptides Biosimilars Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Peptides Biosimilars Players by Revenue
    • 3.1.1 Global Top Peptides Biosimilars Players by Revenue (2016-2021)
    • 3.1.2 Global Peptides Biosimilars Revenue Market Share by Players (2016-2021)
  • 3.2 Global Peptides Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Peptides Biosimilars Revenue
  • 3.4 Global Peptides Biosimilars Market Concentration Ratio
    • 3.4.1 Global Peptides Biosimilars Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Peptides Biosimilars Revenue in 2020
  • 3.5 Peptides Biosimilars Key Players Head office and Area Served
  • 3.6 Key Players Peptides Biosimilars Product Solution and Service
  • 3.7 Date of Enter into Peptides Biosimilars Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Peptides Biosimilars Breakdown Data by Type

  • 4.1 Global Peptides Biosimilars Historic Market Size by Type (2016-2021)
  • 4.2 Global Peptides Biosimilars Forecasted Market Size by Type (2022-2027)

5 Peptides Biosimilars Breakdown Data by Application

  • 5.1 Global Peptides Biosimilars Historic Market Size by Application (2016-2021)
  • 5.2 Global Peptides Biosimilars Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Peptides Biosimilars Market Size (2016-2027)
  • 6.2 North America Peptides Biosimilars Market Size by Type
    • 6.2.1 North America Peptides Biosimilars Market Size by Type (2016-2021)
    • 6.2.2 North America Peptides Biosimilars Market Size by Type (2022-2027)
    • 6.2.3 North America Peptides Biosimilars Market Size by Type (2016-2027)
  • 6.3 North America Peptides Biosimilars Market Size by Application
    • 6.3.1 North America Peptides Biosimilars Market Size by Application (2016-2021)
    • 6.3.2 North America Peptides Biosimilars Market Size by Application (2022-2027)
    • 6.3.3 North America Peptides Biosimilars Market Size by Application (2016-2027)
  • 6.4 North America Peptides Biosimilars Market Size by Country
    • 6.4.1 North America Peptides Biosimilars Market Size by Country (2016-2021)
    • 6.4.2 North America Peptides Biosimilars Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.3 Canada

7 Europe

  • 7.1 Europe Peptides Biosimilars Market Size (2016-2027)
  • 7.2 Europe Peptides Biosimilars Market Size by Type
    • 7.2.1 Europe Peptides Biosimilars Market Size by Type (2016-2021)
    • 7.2.2 Europe Peptides Biosimilars Market Size by Type (2022-2027)
    • 7.2.3 Europe Peptides Biosimilars Market Size by Type (2016-2027)
  • 7.3 Europe Peptides Biosimilars Market Size by Application
    • 7.3.1 Europe Peptides Biosimilars Market Size by Application (2016-2021)
    • 7.3.2 Europe Peptides Biosimilars Market Size by Application (2022-2027)
    • 7.3.3 Europe Peptides Biosimilars Market Size by Application (2016-2027)
  • 7.4 Europe Peptides Biosimilars Market Size by Country
    • 7.4.1 Europe Peptides Biosimilars Market Size by Country (2016-2021)
    • 7.4.2 Europe Peptides Biosimilars Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Peptides Biosimilars Market Size (2016-2027)
  • 8.2 Asia-Pacific Peptides Biosimilars Market Size by Type
    • 8.2.1 Asia-Pacific Peptides Biosimilars Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Peptides Biosimilars Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Peptides Biosimilars Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Peptides Biosimilars Market Size by Application
    • 8.3.1 Asia-Pacific Peptides Biosimilars Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Peptides Biosimilars Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Peptides Biosimilars Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Peptides Biosimilars Market Size by Region
    • 8.4.1 Asia-Pacific Peptides Biosimilars Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Peptides Biosimilars Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Peptides Biosimilars Market Size (2016-2027)
  • 9.2 Latin America Peptides Biosimilars Market Size by Type
    • 9.2.1 Latin America Peptides Biosimilars Market Size by Type (2016-2021)
    • 9.2.2 Latin America Peptides Biosimilars Market Size by Type (2022-2027)
    • 9.2.3 Latin America Peptides Biosimilars Market Size by Type (2016-2027)
  • 9.3 Latin America Peptides Biosimilars Market Size by Application
    • 9.3.1 Latin America Peptides Biosimilars Market Size by Application (2016-2021)
    • 9.3.2 Latin America Peptides Biosimilars Market Size by Application (2022-2027)
    • 9.3.3 Latin America Peptides Biosimilars Market Size by Application (2016-2027)
  • 9.4 Latin America Peptides Biosimilars Market Size by Country
    • 9.4.1 Latin America Peptides Biosimilars Market Size by Country (2016-2021)
    • 9.4.2 Latin America Peptides Biosimilars Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Peptides Biosimilars Market Size (2016-2027)
  • 10.2 Middle East & Africa Peptides Biosimilars Market Size by Type
    • 10.2.1 Middle East & Africa Peptides Biosimilars Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Peptides Biosimilars Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Peptides Biosimilars Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Peptides Biosimilars Market Size by Application
    • 10.3.1 Middle East & Africa Peptides Biosimilars Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Peptides Biosimilars Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Peptides Biosimilars Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Peptides Biosimilars Market Size by Country
    • 10.4.1 Middle East & Africa Peptides Biosimilars Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Peptides Biosimilars Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Sandoz
    • 11.1.1 Sandoz Company Details
    • 11.1.2 Sandoz Business Overview
    • 11.1.3 Sandoz Peptides Biosimilars Introduction
    • 11.1.4 Sandoz Revenue in Peptides Biosimilars Business (2016-2021)
    • 11.1.5 Sandoz Recent Development
  • 11.2 Pfizer
    • 11.2.1 Pfizer Company Details
    • 11.2.2 Pfizer Business Overview
    • 11.2.3 Pfizer Peptides Biosimilars Introduction
    • 11.2.4 Pfizer Revenue in Peptides Biosimilars Business (2016-2021)
    • 11.2.5 Pfizer Recent Development
  • 11.3 Teva Pahrmaceutical
    • 11.3.1 Teva Pahrmaceutical Company Details
    • 11.3.2 Teva Pahrmaceutical Business Overview
    • 11.3.3 Teva Pahrmaceutical Peptides Biosimilars Introduction
    • 11.3.4 Teva Pahrmaceutical Revenue in Peptides Biosimilars Business (2016-2021)
    • 11.3.5 Teva Pahrmaceutical Recent Development
  • 11.4 Celltrion
    • 11.4.1 Celltrion Company Details
    • 11.4.2 Celltrion Business Overview
    • 11.4.3 Celltrion Peptides Biosimilars Introduction
    • 11.4.4 Celltrion Revenue in Peptides Biosimilars Business (2016-2021)
    • 11.4.5 Celltrion Recent Development
  • 11.5 Biocon
    • 11.5.1 Biocon Company Details
    • 11.5.2 Biocon Business Overview
    • 11.5.3 Biocon Peptides Biosimilars Introduction
    • 11.5.4 Biocon Revenue in Peptides Biosimilars Business (2016-2021)
    • 11.5.5 Biocon Recent Development
  • 11.6 Amgen
    • 11.6.1 Amgen Company Details
    • 11.6.2 Amgen Business Overview
    • 11.6.3 Amgen Peptides Biosimilars Introduction
    • 11.6.4 Amgen Revenue in Peptides Biosimilars Business (2016-2021)
    • 11.6.5 Amgen Recent Development
  • 11.7 Samsung Biologics
    • 11.7.1 Samsung Biologics Company Details
    • 11.7.2 Samsung Biologics Business Overview
    • 11.7.3 Samsung Biologics Peptides Biosimilars Introduction
    • 11.7.4 Samsung Biologics Revenue in Peptides Biosimilars Business (2016-2021)
    • 11.7.5 Samsung Biologics Recent Development
  • 11.8 Mylan
    • 11.8.1 Mylan Company Details
    • 11.8.2 Mylan Business Overview
    • 11.8.3 Mylan Peptides Biosimilars Introduction
    • 11.8.4 Mylan Revenue in Peptides Biosimilars Business (2016-2021)
    • 11.8.5 Mylan Recent Development
  • 11.9 Dr. Reddy's Laboratories
    • 11.9.1 Dr. Reddy's Laboratories Company Details
    • 11.9.2 Dr. Reddy's Laboratories Business Overview
    • 11.9.3 Dr. Reddy's Laboratories Peptides Biosimilars Introduction
    • 11.9.4 Dr. Reddy's Laboratories Revenue in Peptides Biosimilars Business (2016-2021)
    • 11.9.5 Dr. Reddy's Laboratories Recent Development
  • 11.10 Stada Arzneimittel AG
    • 11.10.1 Stada Arzneimittel AG Company Details
    • 11.10.2 Stada Arzneimittel AG Business Overview
    • 11.10.3 Stada Arzneimittel AG Peptides Biosimilars Introduction
    • 11.10.4 Stada Arzneimittel AG Revenue in Peptides Biosimilars Business (2016-2021)
    • 11.10.5 Stada Arzneimittel AG Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Peptides Biosimilars market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Peptides Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

    Segment by Type
    Glucagon
    Calcitonin

    Segment by Application
    Oncology
    Chronic Diseases
    Autoimmune Diseases
    Blood Disorders
    Growth Hormone Deficiency
    Infectious Diseases
    Other Diseases

    By Region
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia
    Latin America
    Mexico
    Brazil
    Rest of Latin America
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of MEA

    By Company
    Sandoz
    Pfizer
    Teva Pahrmaceutical
    Celltrion
    Biocon
    Amgen
    Samsung Biologics
    Mylan
    Dr. Reddy's Laboratories
    Celltrion

    Buy now